| __timestamp | MiMedx Group, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 13774000 |
| Thursday, January 1, 2015 | 133384000 | 22479000 |
| Friday, January 1, 2016 | 179997000 | 27388000 |
| Sunday, January 1, 2017 | 220119000 | 35610000 |
| Monday, January 1, 2018 | 258528000 | 49007000 |
| Tuesday, January 1, 2019 | 198205000 | 61139000 |
| Wednesday, January 1, 2020 | 181022000 | 68836000 |
| Friday, January 1, 2021 | 198359000 | 97592000 |
| Saturday, January 1, 2022 | 208789000 | 106903000 |
| Sunday, January 1, 2023 | 211124000 | 120998000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and MiMedx Group, Inc. over the past decade. From 2014 to 2023, MiMedx Group, Inc. consistently outspent Vericel Corporation, with their SG&A expenses peaking in 2018 at approximately 2.6 times that of Vericel's. However, Vericel has shown a remarkable upward trend, with a nearly 800% increase in SG&A expenses from 2014 to 2023. This growth reflects Vericel's strategic investments in expanding its market presence. Meanwhile, MiMedx's expenses have stabilized, indicating a shift towards optimizing operational efficiency. These insights provide a window into the strategic priorities of these companies, highlighting Vericel's aggressive growth strategy and MiMedx's focus on consolidation and efficiency.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited